Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alto-203
- Development stage
- Phase 2
- Lead developer
- Alto Neuroscience
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALTO-203 is a novel, orally administered small molecule developed by Alto Neuroscience for the treatment of major depressive disorder (MDD) and anhedonia. It acts as a histamine H3 receptor inverse agonist, targeting this receptor to potentially improve symptoms of depression and lack of motivation or pleasure. The drug has demonstrated positive emotional and cognitive effects in healthy participants after a single dose and has shown favorable tolerability in Phase 1 trials. As of April 2024, ALTO-203 is being evaluated in Phase 2 clinical studies for its antidepressant potential in patients with MDD and elevated anhedonia.
02
Targets
HRH3 (Histamine Receptor H3)
Beyond the preview
Go deeper on alto-203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alto-203.